Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04, the S&P 500 advancing 1.14% to 7,637.76 and the Nasdaq climbing 1.69% to 26,418.29.
These are the top stocks that gained the attention of retail traders and investors through the day:
Aethlon Medical Inc. (NASDAQ:AEMD)
Aethlon Medical’s stock soared by 374.13%, closing at $6.78, with an intraday high of $9.50 and a low of $6.01. The stock’s 52-week high and low are $41.35 and $1.41, respectively. In the after-hours trading, the stock fell 5.31% to $6.42.
The surge followed the announcement of an all-stock merger with North Immunology Inc., a biotech firm. This merger, supported by $180 million from a private placement, aims to advance North Immunology’s pipeline, particularly its lead drug candidate NOR-101.
Oklo Inc. (NYSE:OKLO)
Oklo’s shares rose by 11.31%, ending the day at $39.65. The stock reached an intraday high of $40.65 and a low of $36.62, with a 52-week high of $193.84 and a low of $34.38.
Oklo shares rose despite no company-specific catalysts, as investors moved into nuclear-related power stocks following the House passage of the Ratepayer Protection Act.
The legislation shifted generation and transmission costs toward large data centers, boosting the broader data-center power theme.
CID HoldCo Inc. (NASDAQ:DAIC)
CID HoldCo witnessed a significant increase of 163.68%, closing at $5.30, with a high of $7.15 and a low of $1.99. The stock’s 52-week high and low are $98.75 and $0.37.
CID HoldCo agreed to acquire Envoy Technologies for $65 million in equity, with the deal expected to close by Oct. 6, expanding the company into shared electric-vehicle infrastructure. The company also converted $1.09 million of senior debt into 2.82 million shares to eliminate default liabilities and raised $500,000 through a convertible note, while presenting a plan to address its Nasdaq listing compliance.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Xenon Pharmaceuticals saw a modest increase of 1.04%, closing at $57.35, with a high of $58.15 and a low of $56.87. The stock’s 52-week high and low are $72.66 and $35.97. In after-hours trading, the stock crashed 25.39% to $42.79.
Xenon Pharmaceuticals submitted an NDA to the Food and Drug Administration for azetukalner in focal seizures, based on positive Phase 2b and Phase 3 data, while its Phase 3 epilepsy studies continued enrolling patients, according to a statement. The company paused enrollment in ongoing depression studies after an analysis of neuropsychiatric adverse events, though existing participants remained active; topline data from the X-NOVA2 MDD study was expected in the first quarter of 2027.
Moderna Inc. (NASDAQ:MRNA)
Moderna’s stock climbed by 8.55%, closing at $158.07, with an intraday high of $161.96 and a low of $149.50. The stock’s 52-week high and low are $176.66 and $22.29.
Moderna shares have risen more than 100% over the past month after the company and Merck reported a Phase 3 success for their personalized mRNA cancer vaccine in combination with Keytruda in high-risk melanoma. The shares have popped over 400% since the year began.
The companies were advancing the treatment across nine trials spanning melanoma, lung, bladder and kidney cancers, while recent analyst actions remained mixed.
Benzinga Edge Stock Rankings indicate Moderna stock has a Momentum score in the 99th percentile.
See More: Top Momentum Stocks
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Zakharchuk / Shutterstock
Login to comment